| 楼正达.阿比特龙治疗转移性去势抵抗性前列腺癌的临床疗效及安全性[J].浙江中西医结合杂志,2019,29(12): |
| 阿比特龙治疗转移性去势抵抗性前列腺癌的临床疗效及安全性 |
| Clinical efficacy and safety of abiraterone for the treatment of metastatic castration-resistant prostate cancerLou Zhengda, Luo Junfeng, Wang Weiqiang, Xu Jian Yiwu Central Hospital, Urology Department 322000 |
| 投稿时间：2019-05-06 修订日期：2019-11-26 |
| DOI： |
| 中文关键词: 醋酸阿比特龙 泼尼松 转移性去势抵抗型前列腺癌（mCRPC） 临床效果 不良反应 |
| 英文关键词: |
| 基金项目: |
|
| 摘要点击次数: 488 |
| 全文下载次数: 1 |
| 中文摘要: |
| 目的 应用醋酸阿比特龙联合泼尼松治疗转移性去势抵抗型前列腺癌(mCRPC)患者,评估其临床效果和安全性。方法 选择2016年7月至2018年2月mCRPC患者84例,随机分为研究组和对照组,每组各42例,对照组应用多西他赛联合泼尼松进行治疗,研究组同时应用醋酸阿比特龙联合泼尼松进行治疗。评估临床疗效、无进展生存期(PFS)、毒性反应,分别于治疗前后检测总前列腺特异性抗原(tPSA)和睾酮水平,评估患者尿流动力学,最大尿流率(MFR)、剩余尿量(PVR),应用Karnofsky(KPS)评分评估患者生活质量。结果 研究组患者近期有效率(RR)和PFS分别为69.05%(29/42)和(9.34±0.71)月,高于对照组54.76%(23/42)和(7.05±0.68)月,差异具有统计学意义(P＜0.05)；研究组治疗后血浆血浆tPSA、睾酮、PVR分别为(13.42±3.70)ng/ml、(0.71±0.15)ng/ml、(24.15±1.91)ml,均低于对照组,研究组MFR、和KPS 评分分别为(14.39±0.84)ml、(68.59±5.22)分,高于对照组,差异具有统计学意义(P＜0.05)。两组患者不良反应比较,差异无统计学意义(P＞0.05)。结论 应用醋酸阿比特龙联合泼尼松治疗mCRPC患者,临床疗效较好,且具有较高的安全性。 |
| 英文摘要: |
| Objective Treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) with abiraterone acetate and prednisone for clinical efficacy and safety. Methods 84 patients with mCRPC from July in 2016 to February in 2018 were randomly divided into study group and control group, with 42 cases in each group.The control group was treated with docetaxel plus prednisone. The study group was treated with abiraterone acetate combined with prednisone.Evaluated clinical efficacy,progression free survival (PFS),toxicity, and total prostate specific antigen (tPSA) and testosterone levels were measured before and after treatment, and urodynamics, maximum urinary flow rate (MFR), and residual urine volume (PVR) were assessed. ), and assessed quality of life by Karnofsky (KPS) score.Results The recent effective rate (RR) and PFS of the study group were 69.05% (29/42) and (9.34±0.71) months respectively, higher than the control group of 54.76% (23/42) and (7.05±0.68) months,the difference was statistically significant(P<0.05).Plasma plasma tPSA, testosterone and PVR in the study group were (13.42±3.70) ng/ml, (0.71±0.15) ng/ml, (24.15±1.91) ml respectively, lower than the control,MFR and KPS scores of the study group were (14.39±0.84) ml and (68.59±5.22), higher than the control group, the difference was statistically significant (P<0.05). There were no significant differences in adverse reactions between two groups (P>0.05).Conclusion The treatment of mCRPC patients with abiraterone acetate combined with prednisone has the better clinical effect and higher safety. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
